Helix Biopharma Corp. (HBPCF), a Toronto-based biopharmaceutical company, recently announced its financial results for the fiscal fourth quarter, revealing a net loss of $3.9 million. This loss translates to 8 cents per share, highlighting challenges the company faced during the quarter. The reported figures underscore ongoing financial pressures, which are not uncommon in the biotechnology...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here